36th week of 2011 patent applcation highlights part 31 |
Patent application number | Title | Published |
20110217213 | METHOD AND APPARATUS FOR MEASURING pH OF LOW ALKALINITY SOLUTIONS - Systems and methods are described for measuring pH of low alkalinity samples. The present invention provides a sensor array comprising a plurality of pH indicators, each indicator having a different indicator concentration. A calibration function is generated by applying the sensor array to a sample solution having a known pH such that pH responses from each indicator are simultaneously recorded versus indicator concentration for each indicator. Once calibrated, the sensor array is applied to low alkalinity samples having unknown pH. Results from each pH indicator are then compared to the calibration function, and fitting functions are extrapolated to obtain the actual pH of the low alkalinity sample. | 2011-09-08 |
20110217214 | PARTICULATE MATTER AND METHODS OF OBTAINING SAME FROM A KRAFT WASTE RECLAMATION - A method for obtaining particulate calcium carbonate having an average particle size less than about 12 microns is provided. The method includes the steps of (1) withdrawing from a pulp mill a mixture containing calcium carbonate; (2) treating the mixture to remove contaminants contained in the mixture to produce a treated mixture containing calcium carbonate and further having a chemical composition and/or purity which substantially inhibits the fusing together of calcium carbonate particulates; (3) recovering from the treated mixture particulate calcium carbonate having an average particle size less than about 12 microns. The calcium carbonate produced has a high surface area to volume ratio and is therefore highly reactive and suitable for numerous applications such as in the treatment of soil, filler paper production, paint production, and contaminant containment in coal stack emission assemblies. | 2011-09-08 |
20110217215 | SUBSTRATE HAVING POROUS SHEET(S) FOR TREATING EXHAUST GASES OF COMBUSTION ENGINES - The object of the invention is a porous sheet(s) for treating exhaust gases of combustion engines in open channels. According to the invention at least part of the porous sheet has a covering support having pores over 10 nm and coarse particles over 1.4 μm. | 2011-09-08 |
20110217216 | Carbon Monoxide Conversion Catalyst - Catalyst articles comprising palladium and related methods of preparation and use are disclosed. Disclosed is a catalyst article comprising a first catalytic layer formed on a substrate, wherein the first catalytic layer comprises palladium impregnated on a ceria-free oxygen storage component and platinum impregnated on a refractory metal oxide, and a second catalytic layer formed on the first catalytic layer comprising platinum and rhodium impregnated on a ceria-containing oxygen storage component. The palladium component of the catalyst article is present in a higher proportion relative to the other platinum group metal components. The catalyst articles provide improved conversion of carbon monoxide in exhaust gases, particularly under rich engine operating conditions. | 2011-09-08 |
20110217217 | Nanocomposite Materials Comprising Metal-Organic-Framework Units and Graphite-Based Materials, and Methods of Using Same - The present invention relates to nanocomposite materials comprising: graphite-based material dispersed among transition metal-organic framework (MOF) units, wherein the graphite-based material is chemically linked to MOF units; wherein the graphite-based material is present in the range of about 5 wt. % to about 60 wt. % of the composite material. | 2011-09-08 |
20110217218 | Systems and Methods for Acid Gas Removal - A method and system for the selective removal of CO | 2011-09-08 |
20110217219 | SCRUBBING SOLUTION CONSISTING OF AQUEOUS AMMONIA SOLUTION AMINES FOR THE SCRUBBING OF GAS AND USE OF SUCH SOLUTION - The invention relates to a process using a solvent combination for the gas scrubbing of industrial gases in order to separate acid gases, particularly including carbon dioxide and hydrogen sulphide. The inventive solvent combination consists of a solution of amines in water, said solution containing ammonia for improving the absorption of CO | 2011-09-08 |
20110217220 | Metal Oxide Compositions for Sequestering Carbon Dioxide and Methods of Making and Using the Same - The present invention is directed to methods of sequestering carbon dioxide using metal oxide compositions, methods of making the metal oxide compositions, and articles comprising the metal oxide compositions. | 2011-09-08 |
20110217221 | METHOD AND CATALYST FOR REMOVAL OF NITROGEN OXIDES IN A FLUE GAS - The invention relates to a method and a catalyst for removal of nitrogen oxides in a flue gas from a combustion engine or gas turbine by injecting a reducing agent and reducing the nitrogen oxides in the presence of a catalyst. The catalyst is a zeolite based catalyst on a corrugated monolithic substrate, the substrate has a density of 50-300 g/l and a porosity of at least 50%. The monolithic substrate is a paper of high silica content glass or a paper of E-glass fibre with a layer of diatomaceous earth or a layer of titania, and the catalyst is a Fe-β zeolite. | 2011-09-08 |
20110217222 | PROCESS FOR THE ACID DIGESTION OF METAL-CONTAINING COMPOUNDS - Aqueous leachant compositions and processes for using the same comprising: (a) providing a metal-containing compound; and (b) subjecting the metal-containing compound to an acid digestion comprising contacting the metal-containing compound with an aqueous leachant; wherein the aqueous leachant comprises a mixture selected from the group consisting of: (i) sulfuric acid and one or more alkanesulfonic acids having alkane moieties selected from the group consisting of propyl, ethyl and methyl groups, at a weight ratio of alkanesulfonic acid to sulfuric acid of 1:1000 to 1:1; (ii) sulfuric acid and one or more salts of alkanesulfonic acids having alkane moieties selected from the group consisting of propyl, ethyl and methyl groups, at a weight ratio of salt of alkanesulfonic acid to sulfuric acid of 1:9 to 1:99. | 2011-09-08 |
20110217223 | ISOTOPICALLY-ENRICHED BORANES AND METHODS OF PREPARING THEM - The invention provides new methods for synthesis of large boron hydride clusters, e.g., boron hydride molecules of the formula B | 2011-09-08 |
20110217224 | SILICON CARBIDE CRYSTAL, METHOD OF MANUFACTURING THE SAME, APPARATUS FOR MANUFACTURING THE SAME, AND CRUCIBLE - A method of manufacturing SiC crystal includes the following steps. A manufacturing apparatus including a crucible having a main body portion and a heat insulating material covering the main body portion is prepared. In the main body portion, seed crystal is arranged opposed to a source material. The source material is heated to sublime and a source gas is precipitated on the seed crystal, to thereby grow SiC crystal. The step of preparing the manufacturing apparatus includes the step of arranging a heat radiation portion higher in thermal conductivity than the heat insulating material on a side of an outer surface of the main body portion on a side of seed crystal and covering the entire outer surface of the main body portion on the side of the seed crystal with the heat radiation portion or with the heat radiation portion and the heat insulating material. | 2011-09-08 |
20110217225 | Method and Apparatus for Refining Metallurgical Grade Silicon to Produce Solar Grade Silicon - A method and apparatus for refining metallurgical silicon to produce solar grade silicon for use in photovoltaic cells. A crucible in a vacuum furnace receives a mixture of metallurgical silicon and a reducing agent such as calcium disilicide. The mix is melted in non-oxidizing conditions within the furnace under an argon partial pressure. After melting, the argon partial pressure is decreased to produce boiling and the process ends with directional solidification. The process reduces impurities, such as phosphorus, to a level compatible with solar-grade silicon and reduces other impurities significantly. | 2011-09-08 |
20110217226 | Method and Apparatus for the Manufacture of High Purity Carbon Monoxide - Method and apparatus of making 99.99% pure gaseous carbon monoxide comprising the steps of degassing liquid formic acid producing degassed liquid formic acid; reacting the degassed liquid formic acid or a degassed gaseous formic acid with a liquid mineral acid at an elevated temperature producing a gas phase comprising carbon monoxide gas and water vapor and a liquid phase; condensing the gas phase producing liquid water and gaseous carbon monoxide; scrubbing the carbon monoxide gas producing a gaseous 99.99% pure carbon monoxide having a purity of at least 99.99%, and, compressing the gaseous 99.99% pure carbon monoxide producing the 99.99% pure gaseous carbon monoxide, wherein the method is performed at least in the substantial absence of metallic nickel, metallic iron, nickel-containing alloys, and, iron-containing alloys from contacting any of the liquids or gases, wherein the Fe(CO) | 2011-09-08 |
20110217227 | COMBINED SOLID WASTE, CARBON DIOXIDE QUICKLIME SPARGING, BRINE WATER, AND REVERSE OSMOSIS/ION EXCHANGE PROCESSES FOR THE PRODUCTION OF SODA CHEMICALS - The proposed invention uses a classical chemical equation where carbon dioxide CO | 2011-09-08 |
20110217228 | FIBER BUNDLE WITH PIECED PART, PROCESS FOR PRODUCING SAME, AND PROCESS FOR PRODUCING CARBON FIBER - A fiber bundle which has a pieced part formed by jetting a pressurized fluid against a fiber-bundle overlap is formed either by directly superposing the ending part of a fiber bundle composed of many fibers on the beginning part of another fiber bundle composed of many fibers or by superposing the end part and the beginning part on a jointing fiber bundle composed of many fibers, whereby the many fibers of the fiber bundles are interlaced with one another to thereby piece up the fiber bundles. The pieced part comprises an opened-fiber part in which the fibers have been opened and interlaced-fiber parts respectively located on both sides thereof, each interlaced-fiber part being composed of a plurality of constituent interlaced parts located apart in the width direction for the fiber bundle. | 2011-09-08 |
20110217229 | METHOD FOR PRODUCING HIGH-PURITY CARBON BLACK - The invention provides a method for producing a purified carbon black by removing metal from the aqueous dispersion of carbon black, wherein the metal is removed by bringing the aqueous dispersion of carbon black into contact with at least one organic acid selected from the group consisting of glycolic acid, ascorbic acid and malonic acid. The invention can provide a method for producing the purified carbon black where the metal components such as iron and the other metals contained as the impurities in carbon black can be reduced. | 2011-09-08 |
20110217230 | METHOD FOR PRODUCING NANOPARTICULATE SOLID MATERIALS - The invention relates to a process for producing nanoparticulate solids by means of a Péclet number-stabilized gas-phase reaction. | 2011-09-08 |
20110217231 | ANTI-TENASCIN MONOCLONAL ANTIBODY THERAPY FOR LYMPHOMA - A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount. Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as | 2011-09-08 |
20110217232 | Method for Determination of the Responsiveness of an Individual to Misletoe Lectin - A method for the determination of the responsiveness of an individual to mistletoe lectin or to (an) mistletoe lectin single chain(s), wherein the expression of a membrane-bound receptor for mistletoe lectin is characteristic of a corresponding responsiveness. | 2011-09-08 |
20110217233 | MODULATION OF INTRACELLULAR SIGNALING - A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. | 2011-09-08 |
20110217234 | IMAGING LIGANDS - Naphthoxazine derivatives which are selective ligands for the dopamine D2 receptor and which carry an 18F radio-label suitable for imaging with PET are described. The compounds of the present invention are thus useful for in vivo diagnostics and in vivo imaging of the dopamine D2 receptor. | 2011-09-08 |
20110217235 | ALPHA 1-3 N-GALACTOSYLTRANSFERASE WITH ALTERED DONOR SPECIFICITIES - The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GaINAc-T) enzymes from alpha 1-3 galactosyltransferase (a3Gal-T) that can transfer 2′-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GaINAc-T. | 2011-09-08 |
20110217236 | RADIATION SENSITIVE LIPOSOMES - The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing, radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents. | 2011-09-08 |
20110217237 | THERAPEUTIC DLL4 BINDING PROTEINS - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 2011-09-08 |
20110217238 | Method of Diagnosing or Prognosing Epithelial Ovarian Cancer - The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of epithelial ovarian cancer (EOC). Optionally, the moiety is an antibody or antigen-binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging EOC cells as well as methods of diagnosing or prognosing EOC in an individual. A further aspect of the present invention provides a method of identifying cells associated with EOC, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. Preferably, the cells to be tested are identified as EOC cells if the expression of Sox11 is up-regulated compared to normal B-cells. Preferably EOC cells are identified as improved recurrence-free survival-associated if expression of Sox11 is up-regulated compared with non-cancerous epithelial ovarian cells. Preferably, EOC cells are identified as diminished recurrence-free survival-associated if expression of Sox11 is similar to, or down-regulated, compared with non-cancerous epithelial ovarian cells. | 2011-09-08 |
20110217239 | SYSTEM AND METHOD OF EVALUATING A PROTEIN OF INTEREST ON TUMOR GROWTH INHIBITION WHILE FOLLOWING THE TUMOR IN VIVO OR IN VITRO - Disclosed herein are systems and methods for evaluating a protein of interest on growth inhibition of a tumor while following the tumor in vivo or in vitro through a co-expressed visible marker. The present disclosure provides an expression composition for stably transforming cells, preferably tumor cells. The expression composition includes two vectors respectively include polynucleotides encoding a protein of interest and a visible marker, wherein each polynucleotide is operably linked to a tet-on system such that the protein of interest and the visible marker are co-expressed upon activation of the tet-on system. The present disclosure also provides stably transfected cell lines, which may be used to access real-time biological processes, including tumor cell proliferation. | 2011-09-08 |
20110217240 | IMAGING NEUROLEPTIC COMPOUNDS - A method for identifying typical and atypical antipsychotics based on their ability to reduce neuronal/glial activity in specific brain regions upon dopaminergic neurotransmission is disclosed. | 2011-09-08 |
20110217241 | CONJUGATES OF 19F MR IMAGING TRACERS FOR USE IN MULTI-CHROMIC MRI IMAGING - Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a | 2011-09-08 |
20110217242 | Phenol with color - 1. Liquefied (or Liquified) Phenol USP (Carbolic Acid Liquefied) is Phenol maintained in a liquid condition by the presence of 10.0% water. Its topical medical use includes P & A (Phenol & Alcohol) procedures, and other procedures necessitating an anesthetic antiseptic, solvent, or cauterant. In treating ingrown nails, it is applied to the nail bed to prevent regrowth of nails. As a colorless solution, it can be difficult to see where an application is going during a procedure. Phenol with color eliminates this problem by creating a readily visible way of identifying where the application is going. | 2011-09-08 |
20110217243 | PHARMACEUTICAL IDENTIFICATION - Disclosed are methods for marking a pharmaceutical product, container or pharmaceutical packaging system with a scent to establish the identity and/or source of the pharmaceutical. | 2011-09-08 |
20110217244 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE - The use of oxidatively transformed carotenoid or a component thereof to enhance the immune response in a subject for the treatment of infection or to enhance the immune response to an antigen in a subject being immunized. Also disclosed are pharmaceutical compositions and kits containing the oxidatively transformed carotenoid. | 2011-09-08 |
20110217245 | Substituted Butanol Derivatives And Their Use As Fragrance And Flavor Materials - The present invention is related to substituted butanol derivatives of the formula: | 2011-09-08 |
20110217246 | DENTURE CARE COMPOSITION - This invention relates to a new denture care composition and method of use. In particular, this invention relates to a film-forming denture care composition that kills odor causing bacteria, maintains prolonged fresh breath for two or more hours and is an effective guard against denture odor. | 2011-09-08 |
20110217247 | Compositions and methods for protection of skin against thermal insult - The present invention provides novel topically-applied skin and face coating and paint compositions comprising near infrared reflecting pigments and hydrogels swollen with aqueous solution and/or with simulated sweat. The invention further provides methods of making and using the compositions. The novel compositions protect the skin of the wearer from damage due to intense external heat or thermal flux and simultaneously divert thermal energy to a complementary evaporative cooling mechanism. The compositions protect skin from external thermal fluxes, conform to skin chemistry, and are easy to apply and remove. | 2011-09-08 |
20110217248 | Topical Composition - Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition. Examplary solvent systems are those for which one of the at least two solvent alcohols is polyethylene glycol, glycerin, butylene glycol, diproylene glycol, propylene glycol, ethanol, isopropanol, or a derivative therof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn. | 2011-09-08 |
20110217249 | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds - The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans. | 2011-09-08 |
20110217250 | COMPOSITION FOR A COSMETIC AND A COSMETIC COMPRISING THE SAME - Present invention provides a composition for a cosmetic comprising a fluorine-containing silicone polymer having a three-dimensional, cross-linked structure, prepared by addition polymerizing the following (A), (B) and (C) and containing 10 to 30 mass % of the fluorine atoms, relative to a total mass of (A) to (C),
| 2011-09-08 |
20110217251 | THERAPEUTIC COMPOSITIONS COMPRISING POLYHYDROXYLTATE FATTY ALCOHOL DERIVATIVES AND USES THEREOF - Therapeutic compositions comprising pharmaceutically effective amounts of isolated polyhydroxylated fatty alcohols, in particular suitable for topical or systemic administration. A method for the isolation of a natural polyhydroxylated fatty alcohol from a fruit or vegetable source is also disclosed. | 2011-09-08 |
20110217252 | COMPOUND USEFUL FOR TREATING CELLULITE - It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite. | 2011-09-08 |
20110217253 | COMPOSITION CONTAINING A BLOCK COPOLYMER AND A SPECFIC NON-VOLATILE OIL - Cosmetic care and/or makeup composition containing a particular block ethylenic copolymer, a hydrocarbon-based non-volatile oil characterized by a Hansen solubility parameter δa ranging from 2 to 7 (J/cm | 2011-09-08 |
20110217254 | ANTIPERSPIRANT PREPARATIONS COMPRISING HYDROTALCITE - Hydrotalcite helps prevent changes in the scent and color of an antiperspirant preparation comprising one or more antiperspirant and/or deodorant active ingredients and a maximum of 5% by weight of water, based on the total mass of the preparation. | 2011-09-08 |
20110217255 | BLOCK COPOLYMERS AND THEIR USE - The present invention relates to a process for the preparation of a crosslinked copolymer with anionogenic/anionic groups by free-radical copolymerization by the method of precipitation polymerization, to the copolymers obtained by this process and to their use. | 2011-09-08 |
20110217256 | CLEAR HAIR GEL FIXATIVES - This invention details the use of a simple blend of polyvinyl formamide and one or more polyvinyl alcohols as the fixative polymer system in a clear hair gel composition. The interaction of the polymer system and gelling agents provides clarity of less than 20 NTU and other physical properties such as good curl compression, resistance to high humidity and resistance to flaking. | 2011-09-08 |
20110217257 | NOVEL 4-ALKYL CYCLOHEXANEPROPANAL COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to novel 4-alkyl cyclohexanepropanal compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the novel compounds. | 2011-09-08 |
20110217258 | Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma - Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described. | 2011-09-08 |
20110217259 | IL-16 as a target for diagnosis and therapy of hematological malignancies and solid tumors - The present invention relates to the field of diagnosis and therapy of hematological malignancies, such as multiple myeloma, as well as solid tumors based on cytokine interleukin-16 (IL-16) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that IL-16 is expressed and secreted at high levels by myeloma cells. Most importantly, the inventors have demonstrated for the first time that IL-16 supports the proliferation of the malignant cells. Therefore, this cytokine represents a particularly advantageous target in cancer therapy and diagnosis. | 2011-09-08 |
20110217260 | METHOD OF ENHANCING EYELASH AND EYE BROW HAIR GROWTH - A method of enhancing eyelash and eye brow hair growth utilizes insulin and/or IFG-1 alone or in combination with other known hair growth promoting therapeutic, pharmaceutical, biochemical and biological agents to increase the effect of various therapeutic hair regrowth strategies to enhance eyelash and eye brow hair growth. | 2011-09-08 |
20110217261 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION - The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity. | 2011-09-08 |
20110217262 | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability - A method of treating an ocular surface disorder in a subject in need of such treatment is provided. The method includes exposing conjunctival tissue of the subject to an effective amount of a vasopermeability agent that increases conjunctival vascular permeability. In some embodiments, the agent is a nitric oxide donor, which may be in a sustained release form. A method of screening a substance for treating an ocular surface disorder is also provided. | 2011-09-08 |
20110217263 | EXPANSION OF HAEMOPOIETIC PRECURSORS - The present invention relates to a method of transplanting haematopoietic precursor cells into a subject in need thereof which involves culturing the haematopoietic precursor cells in the presence of a population of cells enriched for STRO-1 | 2011-09-08 |
20110217264 | METHODS AND COMPOSITIONS FOR DELIVERY OF EXOGENOUS FACTORS TO NERVIOUS SYSTEM SITES - The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems. | 2011-09-08 |
20110217265 | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function - Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent. | 2011-09-08 |
20110217266 | Genomic sequence of avian paramyxovirus type 2 and uses thereof - In this application is described the complete genomic sequence of avian parmyxovirus type 2, strains Yucaipa, England, Kenya and Bangor. The sequences are useful for production of recombinant infective virus, a virus vector, for vaccine development and for therapeutic compositions. | 2011-09-08 |
20110217267 | GENE THERAPY VECTORS AND CYTOSINE DEAMINASES - This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders. | 2011-09-08 |
20110217268 | THERAPY OR PROPHYLAXIS OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH A LYTIC BACTERIOPHAGE SPECIFICALLY AGAINST THE K. PNEUMONIAE - A therapy or prophylaxis of | 2011-09-08 |
20110217269 | METHOD OF FOSTERING THE HEALING OF SKIN WOUNDS USING CELLS OF THE ROOT SHEATH, COMPOSITION AND PREPARATION METHOD - The present invention relates to a method for promoting the healing of skin wounds or the re-establishment of the function of the skin and/or its skin appendices of a second skin area, comprising the step of: applying cells obtained from hair root sheaths of a first skin area of a donor onto a second skin area of a host. It further relates to cells, a preparation, the use of cells as well as a method for preparing a preparation. | 2011-09-08 |
20110217270 | METHODS FOR TREATING TUMORS AND CANCEROUS TISSUES - The invention disclosed herein relates generally to immunotherapy and, more specifically, to therapeutic methods for treating tumors and cancerous tissues by first inducing necrosis or apoptosis (e.g., cryotherapy, chemotherapy, radiation therapy, ultrasound therapy, or a combination thereof applied against at least a portion of the tumor or cancerous tissue), and then delivering one or more se doses of antigen presenting cells (e.g., autologous dendritic cells) intratumorally or proximate to the tumor or cancerous tissue, but only after a selected period of time sufficient for the bioavailability of liberated cancer-specific antigens (monitored over the selected period of time) resulting from the necrosis or apoptosis to be at or near a maximum value. The present invention provides an alternative strategy to the ex vivo loading of target antigen to antigen presenting cells such as, for example, enriched autologous dendritic cells for purposes of enhancing an immune response. | 2011-09-08 |
20110217271 | TREATMENT OF DISEASES OR DISORDERS USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 2011-09-08 |
20110217272 | TREATMENT OF RADIATION INJURY USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 2011-09-08 |
20110217273 | Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient - The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof, which are derived from a natural product, minimize adverse side effects of prior therapeutic agents and safe for the human body. Further, they effectively increase the count of T cells such as CD4+ T cells and decrease the number of HIVs, thereby preventing opportunistic infection, dysneuria, and neoplasia caused by immune incompetence, and ultimately the risk of death. Therefore, they are useful in preventing and treating AIDS, and relieving symptoms of AIDS. | 2011-09-08 |
20110217274 | METHODS FOR PRODUCTION AND USES OF MULTIPOTENT ,PLURIPOTENT, DIFFERENTIATED AND DISEASE-RESISTANT CELL POPULATIONS - The claimed invention is directed towards the generation of pluripotent, multipotent, and/or self-renewing cells which are capable of beginning to differentiate in culture into a variety of cell types and capable of further differentiation in vivo. The claimed invention is also directed towards the generation of desirable, differentiating cell populations transplantable to patients, genetic modification of endogenous cells, and the treatment of patients suffering from diseases that may be ameliorated by these methods. This invention also provides methods for preventing, treating, or retarding disease related to immunodeficiency virus (e.g. HIV-1, HIV-2, SIV, FIV, etc.) infection. | 2011-09-08 |
20110217275 | COMPOSITIONS COMPRISING PROBIOTIC BACTERIA OF THE STRAIN BACILLUS COAGULANS AND OMEGA-3 POLYUNSATURATED FATTY ACIDS OR DERIVATIVES THEREOF - Medicaments and therapeutic compositions contain (1) omega-3 polyunsaturated fatty acids and/or derivatives thereof e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof and (2) a probiotic bacteria of the strain | 2011-09-08 |
20110217276 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PRIMARY HEADACHE AND MIGRAINE - Compositions for the prevention and treatment of primary headache and migraine containing pentacyclic diterpenes obtained from | 2011-09-08 |
20110217277 | DRUG OR DERMATOLOGICAL COMPOSITION CONTAINING AN AVOCADO PEPTIDE EXTRACT FOR TREATING AND PREVENTING PRURITUS - The invention relates to a drug or a dermatological composition containing an avocado peptide extract for treating and/or preventing pruritus, in particular gravidic pruritus, pruritus sine materia, pruritus in newborns, and pruritus originating from a drug. | 2011-09-08 |
20110217278 | Medication and Treatment for Disease - A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 μg vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills. | 2011-09-08 |
20110217279 | USE OF HUMAN BILIVERDIN REDUCTASE AND FRAGMENTS THEREOF FOR THE TREATMENT OF PROTEIN KINASE C-DELTA AND ERK RELATED CONDITIONS - The present invention is directed to methods of modulating PKC-δ activity and PKC-δ/ERK complex activity in cells via biliverdin reductase. Methods and compositions for diagnosing and treating a PKC-δ and PKC-δ/ERK complex related condition are also disclosed. | 2011-09-08 |
20110217280 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS - Provided herein are methods for treating a subject suffering from a neuropsychiatric condition (e.g., schizophrenia). The methods include systemic administration of a pharmacological composition containing a therapeutically effective amount of a PAK activator. | 2011-09-08 |
20110217281 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - A method for diagnosing an early stage melanoma which includes detecting the expression level of dual specificity phosphatase 1 protein (DUSP1) and a method for determining a prognosis for a subject having melanoma which includes detecting the expression level of DUSP1 are disclosed. Also disclosed are pharmaceutical compositions and kits comprised by these methods. | 2011-09-08 |
20110217282 | Novel Toxin-Antitoxin System - Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU. | 2011-09-08 |
20110217283 | STABLE GALENIC FREEZE-DRIED PHARMACEUTICAL PREPARATION OF RECOMBINANT CARBOHYDRATE-BINDING POLYPEPTIDES - The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms. | 2011-09-08 |
20110217284 | Factor IX Variants with Clotting Activity in Absence of Their Cofactor and Their Use for Treating Bleeding Disorders - The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications. | 2011-09-08 |
20110217285 | KERATIN BIOMATERIALS FOR TREATMENT OF ISCHEMIA - Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns. | 2011-09-08 |
20110217286 | STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc. | 2011-09-08 |
20110217287 | Therapeutic composition comprising a botulinum neurotoxin - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 2011-09-08 |
20110217288 | Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease - Novel therapies for the treatment of Fabry disease by using androgen/androgen receptor (AR) pathway-related molecules as biomarkers and use of approaches targeting androgen/AR pathway are presented herein. The involvement of aberrant androgen/AR pathway in Fabry disease has never been previously described. The present invention describes, (i) use of approaches that target androgen/AR pathway as therapeutic treatments for Fabry disease and (2) use of the levels of androgen/AR pathway-related molecules in body fluids or tissues as biomarkers for evaluation of disease progression and efficacy of treatments in Fabry patients. | 2011-09-08 |
20110217289 | Melt-Coated Dosage Forms - Formulations of sparingly water-soluble active ingredientscomprising carrier particles provided with active ingredient-containing coatings, the sparingly soluble active ingredients being embedded in coatings composed of amphiphilic copolymers, and the coatings being applied in the form of a solvent-free melt. | 2011-09-08 |
20110217290 | TREATMENT AND/OR PREVENTION OF PEANUT INDUCED ANAPHYLAXIS - Compositions and methods for the treatment of food allergies, particularly peanut allergy are provided. The compositions and methods are based on the observation that agents which interfere with the association of platelet activating fact (PAF) with its receptor (PAF-R) significantly reduce the severity and duration of anaphylaxis. Combination therapy with a PAF inhibitor and a histamine inhibitor provided an increased beneficial effect compared to treatment alone. | 2011-09-08 |
20110217291 | SOLUBLE HYBRID FCT RECEPTORS AND RELATED METHODS - Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides. | 2011-09-08 |
20110217292 | MONOCLONAL ANTIBODIES AGAINST HMGB1 - In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample. | 2011-09-08 |
20110217293 | Uses of morelloflavone - Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. | 2011-09-08 |
20110217294 | COMBINATION OF HGF INHIBITOR AND HEDGEHOG INHIBITOR TO TREAT CANCER - The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of the Hedgehog signaling pathway. | 2011-09-08 |
20110217295 | TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis. | 2011-09-08 |
20110217296 | METHOD FOR SELECTING PATIENTS FOR TREATMENT WITH AN EGFR INHIBITOR - The present invention relates to cancer diagnostics and therapies and to the detection of alterations in cancer cells that are diagnostic, prognostic or predictive. In particular, the present invention provides a method for detecting and analyzing whether a patient suffering from a cancer is responsive to the treatment with an EGFR inhibitor. In the method, a tissue section from a cancer sample is subjected to assays based on immunohistochemistry and enzymatic metallography. | 2011-09-08 |
20110217297 | METHODS FOR CLASSIFYING AND TREATING BREAST CANCERS - The present invention relates to methods of treating a breast cancer in a subject, methods of identifying a subject with a breast cancer as a candidate for a therapy having efficacy for treating a breast cancer molecular subtype, and methods of selecting a therapy for a subject with a breast cancer. The methods comprise determining the molecular subtype of the breast cancer in the subject. In some embodiments, the methods further comprise administering to the subject a therapy that is effective for treating the molecular subtype of the breast cancer. | 2011-09-08 |
20110217298 | MONOCLONAL ANTIBODIES DIRECTED TO CD20 - The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals. | 2011-09-08 |
20110217299 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-09-08 |
20110217300 | Quinazolinone Compounds and Methods of Use Thereof - The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a quinazolinone compound of the present invention | 2011-09-08 |
20110217301 | METHODS FOR TREATING OR SCREENING FOR COMPOUNDS FOR THE TREATMENT OF SEPSIS - The present invention relates to a method for treating and screening for compounds for the treatment of sepsis. More specifically, the treatment and screening methods are based on the discovery that granzyme B containing platelets (GzmB-platelet) causes apoptosis by direct contact with cells. | 2011-09-08 |
20110217302 | TCR Complex Immunotherapeutics - Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCRα, TCRβ, or CD3ε, along with compositions and methods of use thereof are provided. | 2011-09-08 |
20110217303 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2011-09-08 |
20110217304 | MONOCLONAL ANTIBODIES DIRECTED TO CD52 - The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described. | 2011-09-08 |
20110217305 | ANTI-HER2 ANTIBODIES AND COMPOSITIONS - The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions comprising at least two of said recombinant anti-HER2 antibodies, and use of the antibodies and antibody compositions for treatment of cancer. | 2011-09-08 |
20110217306 | C-TERMINAL EXON 5.4 OF RUNX1/AML1 - The present invention relates to a novel C-terminal exon of RUNX1/AML1, its nucleic acid sequence, its peptide and a full length amino acid sequence comprising the novel C-terminal exon. Furthermore, the invention is directed to an antibody against the C-terminal exon of RUNX1/AML1, a pharmaceutical composition for the treatment of various diseases, among others various tumours and the use of the C-terminal exon for the manufacture of a medicament. The C-terminal exon may also be used for the inhibition of cellular growth and/or induction of apoptosis. Furthermore, the invention relates to a method and a kit for diagnosing a disease, both using the C-terminal exon. | 2011-09-08 |
20110217307 | SYNTHETIC PEPTIDES CORRESPONDING TO OVERLAPPING NEUTRALIZING DETERMINANTS IN THE CBD1 EPITOPE INDUCE BROADLY NEUTRALIZING ANTIBODIES - The present invention relates to chimeric peptides having a caveolin-1 binding domain of an HIV-1 gp41 (CBD1) peptide or a variant of said CBD1, fused to a T helper epitope. In one aspect, the T epitope is from a peptide selected from the group consisting of a tetanus toxin, an HIV-1 Gag p24 and an HIV-1 Env-gp120. Compositions containing these chimeric peptides and pharmaceutical and immunogenic compositions as well as vaccines comprising these chimeric peptides also are part of the present invention. Methods to induce neutralizing antibodies against HIV-1 activity and uses of the chimeric peptides to treat or to prevent HIV-1 infection are also disclosed. | 2011-09-08 |
20110217308 | Compositions and methods using recombinant MHC molecules for the treatment of stroke - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 2011-09-08 |
20110217309 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic methods for predicting the effectiveness of treatment of an ovarian cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cells possess mutant K-RAS. The present invention thus provides a method of identifying patients with ovarian cancer who are most likely to benefit from treatment with an IGF-1R kinase inhibitor. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate this methodology are also provided. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-1R kinase inhibitors, based on a determination of the mutation status of the genes K-RAS, B-RAF, PTEN and PIK3CA, which can be used to identify tumor cell types that will be sensitive to IGF-1R kinase inhibitors, and also those that will be insensitive. | 2011-09-08 |
20110217310 | BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY - Provided is a method and compositions for of treating an inflammatory or autoimmune disease in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD). | 2011-09-08 |
20110217311 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel thienopyrimidine compounds of general formula | 2011-09-08 |
20110217312 | TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS - Immunogenic compositions and methods for eliciting an immune response against | 2011-09-08 |